Comparative analysis of the efficacy of seputinib/serpatinib (Ruitu) and osimertinib

Selpercatinib and Osimertinib are both targeted therapy drugs that have a significant role in the treatment of non-small cell lung cancer (NSCLC). Although they are both targeted therapeutic drugs for lung cancer, there are certain differences in their mechanisms of action, indications and efficacy evaluation.

Seputinib is a targeted inhibitor against RET fusion gene mutations. It is mainly used to treat patients with non-small cell lung cancer who carry RET gene mutations or RET fusions. Seputinib is also approved to treat other cancers that carry RET gene mutations, including certain types of thyroid cancer. RET gene fusion mutation is one of the key factors leading to malignant proliferation of cancer cells. Seputinib inhibits the growth and proliferation of cancer cells by specifically inhibiting RET kinase and blocking its signaling pathway.

Osimertinib is a targeted drug used to treat EGFR mutation-positive non-small cell lung cancer. Especially for drug-resistant patients with T790M mutation, osimertinib has shown a relatively ideal effect. Osimertinib blocks the proliferation of tumor cells by inhibiting the kinase activity of EGFR, thereby inhibiting tumor growth.

The difference in efficacy between the two is mainly reflected in the different indications. Seputinib mainly targets RET fusion mutations, while osimertinib targets EGFR mutations, so they are suitable for different patient groups. Studies have shown that seputinib is particularly effective in RET fusion-positive patients, can effectively control tumor growth, and has relatively low drug resistance. In contrast, the treatment of osimertinib is mainly targeted at patients with EGFR mutations, and osimertinib has shown excellent efficacy in dealing with the problem of resistance to EGFR T790M mutations.

Although the targets of the two are different, they both represent progress in targeted therapeutic drugs. They can all precisely target specific mutation sites in cancer cells and reduce damage to normal cells, thereby improving therapeutic effects and reducing side effects. Due to the difference in indications between the two, doctors usually choose corresponding treatment drugs based on the patient's genetic mutation type.

References:https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-22-2189/3311836/ccr-22-2189.pdf